Polymyxin B sulfate and trimethoprim (PBT) are two antibiotics used to treat a wide range of bacterial infections. PBT has been in use for more than 40 years, and is now the most commonly prescribed antibiotic combination in the United States. PBT is effective against most Gram-positive and Gram-negative bacteria, and has been used to treat a variety of infections, including urinary tract infections, skin and soft tissue infections, and respiratory tract infections. In this comprehensive guide, we will discuss the indications, pharmacology, and clinical use of PBT, as well as potential adverse effects and drug interactions.
PBT is indicated for the treatment of a wide range of bacterial infections, including urinary tract infections, skin and soft tissue infections, and respiratory tract infections. It is also approved for the treatment of certain sexually transmitted diseases, including gonorrhea and chlamydia. PBT is also used off-label to treat a variety of other infections, including meningitis, endocarditis, and sepsis.
PBT is a combination of two antibiotics, polymyxin B sulfate and trimethoprim. Polymyxin B is a polypeptide antibiotic derived from the bacterium Bacillus polymyxa. It works by binding to the outer membrane of Gram-negative bacteria, causing disruption of the cell membrane and leakage of intracellular components. Trimethoprim is a synthetic antibiotic that inhibits the synthesis of dihydrofolate reductase, an enzyme involved in the synthesis of folate, a cofactor for the synthesis of nucleic acids. By inhibiting the synthesis of folate, trimethoprim interferes with the synthesis of nucleic acids, preventing bacterial replication.
PBT is generally well tolerated and is effective against most Gram-positive and Gram-negative bacteria, including many resistant strains. It is usually administered orally, although it can also be administered intravenously. The usual dose is one tablet (500mg polymyxin B sulfate and 200mg trimethoprim) taken twice daily for seven to ten days. The dose may need to be adjusted for patients with renal impairment.
As with any medication, PBT can cause adverse effects. The most common side effects include nausea, vomiting, diarrhea, and rash. Other more serious side effects, such as anaphylaxis and Stevens-Johnson syndrome, have been reported in rare cases. PBT can also interact with other medications, including antacids, diuretics, and warfarin. It is important to tell your doctor about all medications you are taking before starting PBT.
Polymyxin B sulfate and trimethoprim (PBT) is a combination antibiotic used to treat a wide range of bacterial infections. It is generally well tolerated and is effective against most Gram-positive and Gram-negative bacteria, including many resistant strains. While PBT is generally safe and effective, it can cause adverse effects and interact with other medications, so it is important to tell your doctor about all medications you are taking before starting PBT. With proper use, PBT can be a powerful tool in the fight against bacterial infections.
1.
Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC
2.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
3.
Surviving cancer, still suffering: Survey reveals gaps in follow‑up care
4.
Charles III, King of Kings, is Cancerous.
5.
The Truth About Apple AirPods
1.
How Digital Innovation and AI-Powered Case Studies are Revolutionizing Oncology Education?
2.
Advancements in Survival Mechanisms and Prognostic Determinants in Acute Myeloid Leukemia
3.
Unveiling the Hidden Mechanisms of Hemolytic Reactions
4.
Blastic Plasmacytoid Dendritic Cell Neoplasm and the Dawn of AI-powered Diagnostics
5.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Cancer- Q&A Session to Close the Gap
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
3.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
5.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation